Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies-Reference-Cited by-同舟云学术

Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies

Published:2017-04-19 Issue:7 Volume:56 Page:803-813
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Goldwater Ronald,Hussaini Azra,Bosch Bill,Nemeth Paul

Funder

Churchill Pharmaceuticals LLC

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-017-0536-2/fulltext.html

Reference13 articles.

1. International Agency for Research on Cancer. GLOBOCAN cancer fact sheets: prostate cancer. 2016. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx . Accessed 23 Sept 2016.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

3. Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids. 2015;95:80–7.

4. Nussbaum N, George DJ, Abernethy AP, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016;19(2):111–21.

5. Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5(11):610–20.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Encapsulation of Abiraterone Acetate in 2,6 Di-O-Methyl-β-Cyclodextrin for Solubility Enhancement: Synthesis, Characterization, In Vitro Drug Release, and Molecular Docking;BioNanoScience;2024-08-02

2. Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects;Cancer Chemotherapy and Pharmacology;2023-12-29

3. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-10

4. Pharmaceutical Product Characterization and Manufacturability of Surfactant-Enriched Oil Marbles with Abiraterone Acetate;AAPS PharmSciTech;2022-10-07

5. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products;European Journal of Pharmaceutical Sciences;2022-09